In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for ...

In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...

The UK government will contribute up to £50 million of new investment into the scheme, with Lilly contributing up to £35 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...

“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi ...

Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.